DESTINY-Breast03 trial: some questions remain - Authors' reply.

Hurvitz, Sara A; Curigliano, Giuseppe; Egorov, Anton; Ashfaque, Shahid; Cortés, Javier.

Afiliação

Hurvitz SA; Department of Medicine, Division of Hematology-Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA. Electronic address: shurvitz@mednet.ucla.edu.
Curigliano G; European Institute of Oncology, IRCCS, Milano, Italy; Department of Oncology and Hemato-Oncology, University of Milano, Milano, Italy.
Egorov A; Daiichi Sankyo, Basking Ridge, NJ, USA.
Ashfaque S; Daiichi Sankyo, Basking Ridge, NJ, USA.
Cortés J; International Breast Cancer Center, Pangaea Oncology, Quironsalud Group, Barcelona, Spain; Department of Medicine, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain.

Lancet ; 401(10389): 1653-1654, 2023 05 20.

Article em En | MEDLINE | ID: mdl-37210117

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Lancet Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Lancet Ano de publicação: 2023 Tipo de documento: Article